초미세 갑상샘 유두암종에서의 BRAF 돌연변이 검출
The Frequency of BRAF Mutation in Very Small Papillary Thyroid Carcinomas
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background : Papillary thyroid carcinoma (PTC) is the most common malignant tumor of the thyroid and BRAF (V600E) is the most frequent genetic alteration in PTCs. The aim of this study was to investigate the frequency of BRAF mutation, especially in very small PTCs. Methods : We analyzed the presence of the BRAF mutation in PTCs in subgroups defined by tumor size (0.5 cm intervals). Results : Of 140 patients, 85 (60.7%) showed a BRAF mutation. The frequency of BRAF mutation in the subgroup was: 45/70 (64.3%) in tumors less than 0.5 cm in size, 18/ 28 (64.3%) in 0.6-1 cm tumors, 10/22 (45.5%) in 1.1-1.5 cm tumors, and 12/20 (60.0%) in 1.6-2 cm tumors. There was no statistically significant association between BRAF mutation and tumor size (p = 0.44). Similarly, BRAF mutation was not statistically related to age, sex, stage, perithyroidal extension or lymph node metastasis. On multivariate logistic regression analysis, tumor sizes larger than 0.5 cm were associated with lymph node metastasis (odds ratio, 3.79; 95% confidence interval, 1.81 to 7.91; p < 0.01). Conclusions : The BRAF mutation is not related to tumor size even in very small PTCs. The similar frequency of BRAF mutation in very small PTCs suggests that the BRAF mutation is a very early event in the tumorigenesis of PTCs.
Abstract
Background : Papillary thyroid carcinoma (PTC) is the most common malignant tumor of the thyroid and BRAF (V600E) is the most frequent genetic alteration in PTCs. The aim of this study was to investigate the frequency of BRAF mutation, especially in very small PTCs. Methods : We analyzed the presence of the BRAF mutation in PTCs in subgroups defined by tumor size (0.5 cm intervals). Results : Of 140 patients, 85 (60.7%) showed a BRAF mutation. The frequency of BRAF mutation in the subgroup was: 45/70 (64.3%) in tumors less than 0.5 cm in size, 18/ 28 (64.3%) in 0.6-1 cm tumors, 10/22 (45.5%) in 1.1-1.5 cm tumors, and 12/20 (60.0%) in 1.6-2 cm tumors. There was no statistically significant association between BRAF mutation and tumor size (p = 0.44). Similarly, BRAF mutation was not statistically related to age, sex, stage, perithyroidal extension or lymph node metastasis. On multivariate logistic regression analysis, tumor sizes larger than 0.5 cm were associated with lymph node metastasis (odds ratio, 3.79; 95% confidence interval, 1.81 to 7.91; p < 0.01). Conclusions : The BRAF mutation is not related to tumor size even in very small PTCs. The similar frequency of BRAF mutation in very small PTCs suggests that the BRAF mutation is a very early event in the tumorigenesis of PTCs.
참고문헌 (35)
- Welfare and Family Affairs. Annual report of cancer incidence (2007), cancer prevalence (2007) and survival (1993- 2007) in Korea, "Ministry for Health", Ministry for Health, Welfare and Family Affair, ~ (2009)
- "Thyroid cancer: incidence and histological pattern in Korea"[URL]
- Bramley MD, "Papillary microcarcinoma of the thyroid gland", Br J Surg, 83, pp.1674~1683 (1996)
- Ito Y, "An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid", Thyroid, 13, pp.381~387 (2003)
- Sakorafas GH, "Papillary thyroid microcarcinoma:a surgical perspective", Cancer Treat Rev, 31, pp.423~438 (2005)
- Küçük NO, "Treatment for microcarcinoma of the thyroid:clinical experience", Clin Nucl Med, 32, pp.279~281 (2007)
- Roti E, "Clinical and histological characteristics of papillary thyroid microcarcinoma:results of a retrospective study in 243 patients", J Clin Endocrinol Metab, 91, pp.2171~2178 (2006)
- Besic N, "Papillary thyroid microcarcinoma:prognostic factors and treatment", J Surg Oncol, 97, pp.221~225 (2008)
- Davies H, "Mutations of the BRAF gene in human cancer", Nature, 417, pp.949~954 (2002)
- Xing M, "BRAF mutation in thyroid cancer", Endocr Relat Cancer, 12, pp.245~262 (2005)
- Cahill S, "Effect of BRAFV600E mutation on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model", Mol Cancer, 6, pp.21~ (2007)
- 김경희, "Mutations of the BRAF Gene in Papillary Thyroid Carcinoma in a Korean Population", Yonsei Medical Journal, 45(5), pp.818~821 (2004), 연세대학교의과대학
- Kwak JY, "Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma", Radiology, 253, pp.854~860 (2009)
- Park YJ, "Papillary microcarcinoma in comparison with larger papillary thyroid carcinoma in BRAF(V600E)mutation,clinicopathological features,and immunohistochemical findings", Head Neck, 32, pp.38~45 (2010)
- Edge SB, "AJCC cancer staging manual. 7th ed" (2010), Springer-Verlag
- Bongarzone I, "RET", NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family:correlation with clinicopathological features, 1998, pp.4, 223~228
- Soares P, "Sporadic ret-rearranged papillary carcinoma of the thyroid:a subset of slow growing,less aggressive thyroid neoplasms?", J Pathol, 185, pp.71~78 (1998)
- Kimura ET, "High prevalence of BRAF mutations in thyroid cancer:genetic evidence for constitutive activation of the RET", PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma, 2003, pp.63, 1454~1457
- Soares P, "BRAF mutations and RET", PTC rearrangements are alternative events in the etiopathogenesis of PTC, 2003, pp.22, 4578~4580
- Adeniran AJ, "Correlation between genetic alterations and microscopic features,clinical manifestations,and prognostic characteristics of thyroid papillary carcinomas", Am J Surg Pathol, 30, pp.216~222 (2006)
- Mayr D, "KRAS and BRAF mutations in ovarian tumors:a comprehensive study of invasive carcinomas,borderline tumors and extraovarian implants", Gynecol Oncol, 103, pp.883~887 (2006)
- Brose MS, "BRAF and RAS mutations in human lung cancer and melanoma", Cancer Res, 62, pp.6997~7000 (2002)
- Goldenberg D, "The V599E BRAF mutation is uncommon in biliary tract cancers", Mod Pathol, 17, pp.1386~1391 (2004)
- 나소영, "갑상선 유두암에서의 BRAF 변이와 예후인자와의 관계", 대한내분비학회지, 20(3), pp.224~229 (2005), 대한내분비학회
- Kim TY, "The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma", Clin Endocrinol(Oxf), 63, pp.588~593 (2005)
- Kim KH, "Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto’s thyroiditis", Pathol Int, 55, pp.540~545 (2005)
- Kim TY, "The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma", Clin Endocrinol(Oxf), 65, pp.364~368 (2006)
- Park SY, "Analysis of differential BRAF(V600E)mutational status in multifocal papillary thyroid carcinoma:evidence of independent clonal origin in distinct tumor foci", Cancer, 107, pp.1831~1838 (2006)
- 민혜숙, "Immunohistochemical and Molecular Characteristics of Follicular Patterned Thyroid Nodules with Incomplete Nuclear Features of Papillary Thyroid Carcinoma", The Korean Journal of Pathology, 43(6), pp.495~502 (2009), 대한병리학회
- Kim SK, "Clinical and pathological features and the BRAF(V600E)mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis", Thyroid, 19, pp.137~141 (2009)
- Nikiforova MN, "BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas", J Clin Endocrinol Metab, 88, pp.5399~5404 (2003)
- Namba H, "Clinical implication of hot spot BRAF mutation,V599E,in papillary thyroid cancers", J Clin Endocrinol Metab, 88, pp.4393~4397 (2003)
- Puxeddu E, "BRAF(V599E)mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas", J Clin Endocrinol Metab, 89, pp.2414~2420 (2004)
- Lee X, "Analysis of differential BRAF(V600E)mutational status in high aggressive papillary thyroid microcarcinoma", Ann Surg Oncol, 16, pp.240~245 (2009)
- Ugolini C, "Presence of BRAF V600E in very early stages of papillary thyroid carcinoma", Thyroid, 17, pp.381~388 (2007)